News &amp; Updates

One-month treatment with dual antiplatelet therapy (DAPT) results in similar adverse events and a reduction in total bleeding risk when compared with prolonged DAPT, a study has shown.

Study ties energy drink intake to unhealthy lifestyle in young individuals

19 Jun 2025 by

A study presented at ESPGHAN 2025 reports that schoolchildren who consume energy drinks have unhealthier lifestyles and a different cardiovascular risk profile than their counterparts who do not or rarely consume energy drinks.

19 Jun 2025

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

For patients with schizophrenia being treated with clozapine who have high BMI, semaglutide delivers weight-loss benefits without affecting psychotic symptoms or altering clozapine concentrations, according to the double-blind, phase II COaST study.

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

Treatment with sildenafil citrate during labour falls short of reducing the incidence of adverse perinatal outcomes potentially related to intrapartum hypoxia, according to a study.

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

The investigational influenza–COVID-19 combination vaccine mRNA-1083 has demonstrated noninferiority to recommended standard-care flu and COVID-19 vaccines, with higher immune responses and an acceptable safety profile in adults at least 50 years of age, according to the results of a phase III trial.

First-line methotrexate on par with prednisone for sarcoidosis

The use of methotrexate as a first line of treatment for patients with pulmonary sarcoidosis delivers similar efficacy to prednisone as measured by forced vital capacity after 24 weeks, results of the PREDMETH trial have shown.

18 Jun 2025

Digital therapy improves life quality of patients with pulmonary fibrosis

A novel digital psychological therapy, named Almee, demonstrates efficacy in improving health-related quality of life (HRQOL) in patients with pulmonary fibrosis, irrespective of antifibrotic treatment use, reports a study presented at ATS 2025.

Inclisiran superior to ezetimibe in LDL-C reduction in patients without ASCVD

Treatment with inclisiran monotherapy demonstrates good tolerability and better reduction in low-density lipoprotein cholesterol (LDL-C) levels when compared with ezetimibe and placebo in patients without atherosclerotic cardiovascular disease (ASCVD), reports a study.

RSV-ARI nearly triples mortality risk in new study

Acute respiratory infection caused by respiratory syncytial virus (RSV-ARI) nearly triples the risk of death, particularly among individuals with chronic underlying respiratory conditions, as shown in a nationwide cohort study in Denmark.

Coil plus glue therapy beneficial for gastric varices

Cyanoacrylate (CYA) injection delivers better results when augmented with endoscopic ultrasonography (EUS)-guided coil embolization for gastric variceal obliteration in a single-centre study.